文献类型： 外文期刊

作者： Lei, Qingchun ¹ ; Zhou, Wenhui ² ; Liu, Wenwen ² ; Li, Yixin ² ; Qi, Nanchang ⁴ ; Li, Qiangfeng ¹ ; Ding, Lei ² ; Huang, Xiaobin ⁵ ; Li, Yu ⁶ ; Wu, Jin ¹ ;

作者机构： 1.Puer Peoples Hosp, Dept Neurosurg, Puer 665000, Yunnan, Peoples R China

2.Yunnan Univ, Sch Life Sci, Kunming 650091, Yunnan, Peoples R China

3.Yunnan Univ, Sch Med, Kunming 650091, Yunnan, Peoples R China

4.First Peoples Hosp Kunming, Clin Lab, Kunming 650021, Yunnan, Peoples R China

5.Kunming Med Univ, Affiliated Hosp 2, Dept Neurosurg, Kunming 650000, Yunnan, Peoples R China

6.Yunnan Acad Agr Sci, Biotechnol & Germplasm Resources Inst, Yunnan Prov Key Lab Agr Biotechnol, Kunming 650223, Yunnan, Peoples R China

7.Puer Peoples Hosp, Dept Neurosurg, 44 ZhenXing Rd, Puer 665000, Yunnan, Peoples R China

8.Biotechnol & Germplasm Resources Inst, Yunnan Acad Agr Sci, Yunnan Prov Key Lab Agr Biotechnol, 2238 Beijing Rd, Kunming 650223, Yunnan, Peoples R China

关键词： Glioblastoma (GBM); microRNA (miRNA; miR); Oncomir and tumor suppressor miRNAs; GBM microenvironment; miRNA-based therapy; Nanoparticles (NPs)

期刊名称：EUROPEAN JOURNAL OF PHARMACOLOGY （ 影响因子：5.195； 五年影响因子：4.721 ）

ISSN： 0014-2999

年卷期： 2023 年 938 卷

页码：

收录情况： SCI

摘要： Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor and is characterized by high mortality and morbidity rates and unpredictable clinical behavior. The disappointing prognosis for patients with GBM even after surgery and postoperative radiation and chemotherapy has fueled the search for specific targets to provide new insights into the development of modern therapies. MicroRNAs (miRNAs/miRs) act as oncomirs and tumor suppressors to posttranscriptionally regulate the expression of various genes and silence many target genes involved in cell proliferation, the cell cycle, apoptosis, invasion, stem cell behavior, angio-genesis, the microenvironment and chemo-and radiotherapy resistance, which makes them attractive candidates as prognostic biomarkers and therapeutic targets or agents to advance GBM therapeutics. However, one of the major challenges of successful miRNA-based therapy is the need for an effective and safe system to deliver therapeutic compounds to specific tumor cells or tissues in vivo, particularly systems that can cross the blood-brain barrier (BBB). This challenge has shifted gradually as progress has been achieved in identifying novel tumor-related miRNAs and their targets, as well as the development of nanoparticles (NPs) as new carriers to deliver therapeutic compounds. Here, we provide an up-to-date summary (in recent 5 years) of the current knowledge of GBM-related oncomirs, tumor suppressors and microenvironmental miRNAs, with a focus on their potential applications as prognostic biomarkers and therapeutic targets, as well as recent advances in the development of carriers for nontoxic miRNA-based therapy delivery systems and how they can be adapted for therapy.